Background: Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC.
introduction
The epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib (Iressa, AstraZeneca, Macclesfield, UK) and erlotinib (Tarceva; F. Hoffmann-La Roche, Basel, Switzerland), have demonstrated activity in 10% of unselected non-small-cell lung cancer (NSCLC) patients. Several clinical and biological features have been shown to be associated to benefit from EGFR-TKIs and some biological factors have been associated with resistance. The EGFR20-T790M mutation is mainly associated with secondary resistance to EGFR-TKIs in NSCLC [1] [2] [3] , whereas KRAS mutations are associated with primary resistance [4, 5] .
Persistent concomitant activity of the ERK and AKT kinase pathways also contributes to resistance to EGFR-TKIs in NSCLC cells [6, 7] . Furthermore, SRC activation has been shown to induce gefitinib resistance by modulation of both AKT and ERK signaling pathways in human gallbladder adenocarcinoma cells [8] , and oncogenic SRC and RAS proteins may induce the epithelial-mesenchymal transition (EMT) that is associated with loss of E-cadherin complexes at cell-cell adhesions and, consequently, with an increased invasive and metastatic potential [9] . A restored E-cadherin expression increased EGFR-TKIs sensitivity in lung cancer cells [10] , while NSCLC patients with a strong E-cadherin staining had a significantly longer time to progression (TTP) and a trend toward longer survival with erlotinib/chemotherapy treatment versus chemotherapy alone [11] .
The cMET tyrosine kinase receptor, normally expressed by epithelial cells, is overexpressed and amplified in a variety of human tumors, including NSCLC [12] [13] [14] [15] . cMET stimulation induces specific phosphorylation of several tyrosine residues (Y1003-Y1313-Y1230/1234/1235-Y1349-Y1365), which, in turn, activate multiple downstream signaling pathways, including the RAS/ERK, PI3K/AKT, and cSRC kinase pathways [16] . Through SRC activation, cMET is considered an EMT promoter [16] . High levels of hepatocyte growth factor (HGF) (the cMET ligand) and intratumoral cMET expression have been associated with a more aggressive biology and a worse prognosis in NSCLC [17] . HGF/cMET pathway alterations may confer a substantial growth advantage and invasive potential to NSCLC cells. In addition, recent studies have demonstrated that targeted cMET inhibition by different therapeutic strategies, including small interfering RNA, small molecules [15] , and specific antibodies [18] , leads to decreased NSCLC cell growth and viability. Engelman et al. [19] reported that cMET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line. Moreover, cMET inhibition with a cMET tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity. The aim of this study was to investigate tumor samples of EGFR-TKI-treated NSCLC patients for potential biological markers of intrinsic EGFR-TKI resistance, especially related to EMT. Given the significant association observed between strong cMET[pY1003] membrane staining and progressive disease (PD) and shorter TTP, we also evaluated the effect of the specific cMET antibody DN-30 combined with gefitinib in a panel of NSCLC cells.
materials and methods

patient populations
We evaluated 51 NSCLC patients treated within the expanded access study of gefitinib at Humanitas Clinical Institute (Rozzano, Milan, Italy). The protocol was approved by the institutional Medical Ethical Committee. Written informed consent was obtained from each patient. Patients received gefitinib 250 mg/day orally and were evaluated for response every 2 months according to the response evaluation criteria in solid tumors criteria [20] . To better assess the incidence of strong cMET[pY1003] expression in a larger NSCLC population, we also evaluated the cMET[pY1003] expression in tumors from two additional series treated at the Vrije Universiteit Medical Center (Amsterdam, The Netherlands): 27 advanced NSCLC patients treated with gefitinib or erlotinib and 71 radically resected NSCLC patients.
tissue microarray construction
Paraffin-embedded tumor specimens of the first series of 51 patients were collected. A pathologist selected areas for 1-mm 2 punches from tumor cores, tumor borders, and normal tissue to include in recipient tissue array block using a specific instrument (Beecher Instruments, Sun Prairie, WI).
immunohistochemical staining [15] . At present, there are no validated scoring systems for interpreting immunohistochemical staining for pAKT, pERK, E-cadherin, SRC, or pMET. Since activation of AKT by phosphorylation results in its translocation from the cytoplasm to the nucleus, samples were considered pAKT positive if nuclear staining was present [21, 22] ; for pERK, we used a system on the basis of the staining intensity as previously described [23] ; the same scoring system was carried out for cytoplasm SRC expression, while for E-cadherin and pMET, we used a scoring system on the basis of the membrane staining intensity [11, 15] ; samples were considered pMET positive if membrane staining was strong (score 3+) ( Figure 1 ).
FISH analysis
A homebrew MET FISH probe developed using the bronchioloalveolar carcinoma (BAC) clone RP11-95I20 (CHORI, Oakland, CA) was used for this study. DNA from single colonies from the BAC clone was confirmed to encompass the MET gene sequences by PCR with two sets of primers for better specificity (MET5#-end: forward-CCAGTCAGGCCGCGTTGTTTATTT, reverse-AGTTATCATTTCCCAAGTGCCAGG; MET3#-end: forward-TGTCCCGGATATCAGCGATCTTCT, reverse-AAGCCTCTGGTTCTGATGCTCTGT). The MET-DNA was labeled with SpectrumRed-conjugated deoxi-uridintriphosphates by nick translation using the Vysis Nick Translation Kit (Abbott Molecular, Des Plaines, IL) and ethanol precipitated using herring sperm DNA (1 : 50) as carrier and human Cot-1 DNA for blocking of repetitive sequences. The DNA pellet was diluted in hybridization mix (50% formamide/10% dextran sulphate/2X SSC). The final MET/CEP7 probe set was prepared with the homebrew SR-MET and CEP7 labeled in SpectrumGreen (Abbott Molecular). 
mutation analysis
Total genomic DNA was isolated using the QIAamp DNA extraction kit (Qiagen, Venlo, The Netherlands). Nested PCR to amplify EGFR (exons 18-21) and KRAS (exons 1, 2) were carried out as previously described [4, 8] . cMET mutation analysis was carried out by direct sequencing, using the following primer sets for cMET exons 14 and 15 (juxtamembrane domain): hu-cMET-ex14F, 5#-CTTTAACAAGCTCTTTCTTTCT-3#; hu-cMET-ex14R 5#-TGTATAGGTATTTCTCAGAA-3#; hu-cMET-ex15F 5#-TTGTTCTTTAATAATTTTC-3#; hu-cMET-ex15F 5#-GAGTCGAAAAACAATTTATGCT-3#. Sequencing of PCR products was carried out as previously described [24] .
lung cancer cell lines and culture conditions
Cell lines were purchased from the American Type Culture Collection (Manassas, VA) and maintained as previously described [23] . The human NSCLC cell lines NCI-H460 (H460), NCI-H1703 (H1703), NCI-H292 (H292), NCI-H1650 (H1650), NCI-H322 (H322), NCI-H3255 (H3255) and NCI-H1975 (H1975) and the SCLC cell line NCI-H69 (H69) were cultured in RPMI-1640, while A549, SW1573, Calu-1, and Calu-6 were cultured in DMEM as previously described [23] .
western blot
In all, 1 · 10 6 cells were plated, grown, and stimulated with 40 ng/ml HGF (Sigma Chemical Co., Zwijndrecht, The Netherlands) as previously described [15] . The whole-cell protein extracts were transferred to nitrocellulose membranes that were incubated overnight at 4°C with specific primary antibodies (anti-cMETc-12-Santa Cruz Biotechnology-1 : 1000 dilution; anti-cMET[pY1003]-BioSource International-1 : 1000 dilution; anti-a-tubulin-Sigma-1 : 200 dilution) and then with the appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technologies) (1 : 2000 dilution) and detection was carried out [23] .
cytotoxicity assay and pharmacological interaction study
Gefitinib was a generous gift from AstraZeneca. DN-30 is a mAb against the cMET extracellular domain, which behaves as a partial agonist, inducing receptor phosphorylation but being unable to trigger the whole set of downstream biological effects [24] . The drugs were diluted in fresh medium before each experiment. A549, SW1573, H460, H292, and H1650 cells were plated and treated with gefitinib (0.01-100 lM) with and without HGF (40 ng/ml) and DN-30 (80 lg/ml) and their combinations, as indicated, as previously described [23] . Each experiment was carried out in two replicate wells for each drug concentration and repeated at least three times. After drug exposure, an MTT assay [MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide, Sigma] was carried out as previously described [23] . DN-30 (80-1500 lg/ml) cytotoxicity was also evaluated by MTT. Absorbance values were expressed as the percentage of the untreated controls, and the 50% inhibitory concentration of cell growth (IC 50 ) relative to untreated cultures was calculated. Drug interaction between gefitinib and DN-30 was assessed, at a nonconstant concentration ratio, using the combination index (CI) method [25] .
statistical analysis
Patient groups were compared with the Fisher's exact or v 2 tests when appropriate. Correlations were considered significant at the <0.05 level (two tailed). Survival curves were constructed using the Kaplan-Meier method, and differences between groups were analyzed using the log-rank test. Multivariate analysis was carried out using the Cox proportional hazards model. Only variables significant at the P < 0.05 level in the univariate analyses were entered into the Cox regression analysis. We carried out manual backward elimination using likelihood ratio tests with a significance level of 0.05. All statistical analyses were carried out using SPSS software (version 14.0; SPSS Inc., Chicago, IL).
results Tables 1 and 2 summarize the outcome according to clinical and biological characteristics of the 51 advanced NSCLC patients treated with gefitinib. No statistically significant association between clinical and biological characteristics was observed. overexpression had PD to the treatment (four of four patients; P = 0.019) and a shorter TTP (P = 0.0416). Of 27 additional advanced/metastatic NSCLC patients treated with erlotinib or gefitinib, two (7.5%) had cMET[pY1003] overexpression and both had PD. Among 71 NSCLC patients treated with radical surgery, only three (4%) had cMET[pY1003] overexpression. The overall frequency of cMET[pY1003] overexpression was 6% (nine of 149 patients). Table 3 summarizes the clinical and biological characteristics of these nine patients. 
multivariate analysis
We carried out two different Cox regression analyses to evaluate the risk of disease progression and the risk of death entering only variables that were significantly associated with TTP in the univariate model in the first analysis and with OS in the second analysis (Table 4) 
in vitro studies
Characterization and gefitinib IC 50 s of the cell lines used have been reported previously [6, 23] . Figure 2A shows the cMET protein expression. Gefitinib induced 50% growth inhibition in NSCLC cells at concentrations ranging from 0.1 to 24 lM in H1650 and H460 cells, respectively ( Figure 2D ). DN-30 treatment resulted in a modest inhibition of cell growth ( Figure 2B ). However, 80 lg/ml DN-30 was able to induce cMET down-regulation, as detected by western blot in SW1573 cells ( Figure 2C ). The activity of gefitinib was slightly reduced by HGF, while the addition of DN-30 enhanced the growth inhibition in H460, SW1573, A549, and H292 cells, with IC 50 s ranging from 0.06 lM (H292) to 18 lM (H460). The CI calculation showed a synergistic effect in all these cells (CI < 1, Figure 2E ). In contrast, the H1650 cells, negative for cMET[pY1003] expression, showed negligible cell growth Male  Female  Male  Male  Male  Male  Male  Female  Male  Histology  ADC  SCC  ADC  ADC  ADC  Other  Other  SCC  SCC  Stage  IV  IV  IV  IV  ND  ND  I  I 
Pt + number, patient from the first series of 51 patients treated with gefitinib; Pt + letter, patient from the second series of 27 patients treated with gefitinib or erlotinib; Pt R, patient from the resected group; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ND, not done; PD, progressive disease; UT, untreated; wt, wild type; MUT, mutated. 
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reduction by the addition of DN-30 to gefitinib, and the pharmacological interaction study demonstrated antagonism (CI > 1, Figure 2E ). . Drug interaction between gefitinib and DN-30 was assessed, at a nonconstant concentration ratio, using the CI, where CI < 1, CI = 1, and CI > 1 indicates synergistic, additive, and antagonistic effects, respectively [25] . The CI calculation showed a synergistic effect in A549, SW1573, H460, and H292 cells (CI < 1). In contrast, the H1650 cells, negative for cMET[pY1003] expression, showed negligible cell growth reduction by the addition of DN-30 to gefitinib, and the pharmacological interaction study demonstrated antagonism (CI > 1). Columns, mean values obtained from three independent experiments; bars, SE.
original article Annals of Oncology is not internalized, it remains tyrosine phosphorylated inducing a potentially oncogenic overstimulation. Although we did not find a significant correlation between activated cMET, cSRC, and the E-cadherin, the majority of patients with cMET[pY1003]-positive tumors in the three different series of patients analyzed had positive cSRC expression and negative E-cadherin, consistent with the role of cMET activation in EMT. Interestingly, all these patients presented typical EGFR-TKIs nonresponder characteristics, such as smoker status, absence of EGFR mutations, and presence of KRAS mutations. Moreover, pAKT and pERK were both positive in six of nine patients, supporting the notion that persistent activity of both RAS/ERK and PI3K/AKT kinase pathways contributes to EGFR-TKIs resistance in NSCLC cells [6, 7, 9] . Recently, Engelman et al. [19] reported that 20% of lung cancers with acquired resistance to gefitinib or erlotinib had cMET amplification and that cMET-driven gefitinib resistance was mediated through ERBB3/PI3K/Akt activation. In our study, one patient harboring EGFR mutation and exhibiting high MET copy numbers experienced PD. However, among the patients with cMET[pY1003] strong overexpression, three of four analyzed by FISH exhibited also high MET copy numbers and seven of nine (78%) had also pAKT-positive expression. None of these patients harbored EGFR19 mutations or experienced some benefit from EGFR-TKIs when treated, suggesting that cMET activation may promote primary as well as acquired EGFR-TKI resistance. Given the small number of patients with cMET[pY1003], our findings will need to be reproduced in larger cohort of patients treated with EGFR-TKIs. We observed cMET[pY1003] expression in 45% (five of 11) of NSCLC cell lines and cMET[pY1003]-positive NSCLC cells were associated with other biological features typical for EGFR-TKI resistance, such as presence of KRAS mutations. A549, SW1573, and H460 cells, with a strong cMET[pY1003] expression and the presence of KRAS mutation, showed gefitinib resistance.
Engelman et al. [19] reported that cMET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line and a cMET tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity. In our study, the gefitinib-DN-30 combination demonstrated a synergistic effect in H460, SW1573, A549, and H292 cells, with IC 50 ranging from 0.06 lM in H292 cells (wild-type KRAS), to 18 lM in H460 cells (mutant KRAS). Interestingly, the greater difference between cytotoxicity curves was recorded at gefitinib concentration between 0.1 and 1 lM, which are clinically achievable (1 lM). The gefitinib-DN-30 combination proved to be particularly effective in SW1573 cells, which have the highest cMET[pY1003] expression and carry a KRAS mutation [19, 26] . In contrast, in the H1650 cells, which are negative for cMET[pY1003] expression and carry an EGFR19 deletion, the addition of DN-30 to gefitinib led to an antagonistic effect.
Our data indicate that activated cMET, indicated by cMET[pY1003] strong overexpression, is a possible mechanism of gefitinib resistance in a small percentage of NSCLC patients and treatment with combinations of EGFR-TKIs and cMET inhibitors could be a promising approach to circumvent EGFRTKIs resistance in this subset of patients. 
